This prospective, double-blind, parallel-group study randomized patients with moderate hypertension (seated systolic blood pressure (SeSBP) 160-179 mm Hg when seated diastolic blood pressure (SeDBP) o110 mm Hg; or SeDBP 100-109 mm Hg when SeSBP o180 mm Hg) 3:1:1 to treatment with irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg combination therapy (n ¼ 328), irbesartan 300 mg monotherapy (n ¼ 106) or HCTZ monotherapy 25 mg (n ¼ 104). Treatment was initiated at half dose, with forced titration to full dose after two weeks followed by ten further weeks' treatment. The primary efficacy variable was the mean reduction in SeSBP from baseline to week 8. Baseline characteristics were similar between groups, with mean baseline blood pressure approximately 162/98 mm Hg; the mean age was 55 years. At week 8 there was a reduction in SeSBP of 27.1 mm Hg with irbesartan/HCTZ, compared with 22.1 mm Hg with irbesartan monotherapy (P ¼ 0.0016) and 15.7 mm Hg with HCTZ (Po0.0001). Both the rate of decline and the total degree of decline achieved were greatest with irbesartan/ HCTZ and least with HCTZ. A significantly greater percentage of patients reached a treatment goal of SeSBP o140 mm Hg and SeDBP o90 mm Hg by week 8 with irbesartan/HCTZ (53.4%), compared with irbesartan (40.6%; P ¼ 0.0254) and HCTZ (20.2%; Po0.0001) alone. Treatment was well tolerated in all three-treatment groups with a slight increase in adverse events in the combination therapy group. In conclusion, irbesartan/HCTZ (300/25 mg) is well tolerated and achieves rapid and sustained reductions in both systolic blood pressure and diastolic blood pressure in patients with moderate hypertension.
Introduction
The reported prevalence of hypertension varies widely between countries, but is increasing globally as populations age and the dietary and lifestyle preferences typical of industrialized countries become more widespread. 1, 2 The number of adults with hypertension was recently predicted to exceed 1.5 billion worldwide by 2025. 3 Alongside this failure of prevention, blood pressure is also poorly controlled in most countries. Studies in both Europe and the United States have reported that only around 25% of all hypertensives and 50% of treated patients have controlled blood pressure, [4] [5] [6] [7] while further European studies have suggested that true rates of control may be significantly lower. [8] [9] [10] The reasons for poor blood pressure control rates are complex. In part, they reflect the impact of structural and economic factors on access to health care, but local clinical, prescriber and patient factors that undermine the adequacy of treatment are also significant. These include patient non-adherence with therapy and physician inertia, particularly with regard to the need to increase the dose of antihypertensive treatment until goals are achieved. 5, 11 To address the problem of persistently poor control rates, a working party representing nine international hypertension, cardiology and healthcare societies recently called for renewed emphasis on the basic principles of hypertension management. One of their key recommendations was to restate the need for a clear and unambiguous commitment to the aggressive, early and well-tolerated treatment of hypertension to goal. 12 The majority of patients with hypertension require two or more antihypertensive medications to achieve blood pressure targets. 13 Indeed, by combining two agents with different modes of action, it is possible to obtain additive or synergistic blood pressure lowering. 14 There is thus a clear rationale for treating patients with moderate or severe hypertension with a combination of drugs from the outset of treatment, provided that such therapy is well tolerated. Current JNC-7 and European Society of Hypertension guidelines both recommend initial combination therapy for patients with moderate or severe hypertension, in whom blood pressure exceeds the goal by 20/ 10 mm Hg or greater. 15, 16 When combination therapy is administered, fixed-dose combinations are more convenient to patients and may improve treatment adherence. 17 A fixed-dose combination of an angiotensin receptor blocker (ARB) with a thiazide, typically hydrochlorothiazide (HCTZ), is a widely used strategy in hypertension management. However, there is a need for further data for ARB/thiazide fixed-dose combination therapy in patients with moderate hypertension, including in the context of initial therapy.
Irbesartan is a potent and well-tolerated ARB that is widely used in fixed-dose combination form with HCTZ. Clinical studies of irbesartan/HCTZ suggest that this combination is not only clinically effective, but also has a favourable safety profile, 18 producing significantly greater dose-dependent reductions in blood pressure compared with monotherapy [19] [20] [21] while attenuating some of the side effects (for example, hypokalaemia) associated with HCTZ. 21 Here, we investigate the efficacy, safety and tolerability of high-dose irbesartan/HCTZ in patients with moderate hypertension, a high proportion of whom were overweight, with dyslipidaemia and/or diabetes.
Materials and methods
The study was conducted in adult patients aged 18 years or older with moderate hypertension that at enrolment was either untreated for at least 4 weeks or uncontrolled by monotherapy. Monotherapy was defined as treatment with a single antihypertensive drug for at least 4 weeks; fixed-dose combination therapy was not considered monotherapy. Untreated patients were enrolled if they had moderate hypertension (seated systolic blood pressure (SeSBP) 160-179 mm* Hg or seated diastolic blood pressure (SeDBP) 100-109 mm Hg). Patients on monotherapy could be enrolled if they had SeSBP 150-179 mm Hg or SeDBP 95-109 mm Hg.
Patients with severe hypertension (SeSBPX 180 mm Hg or SeDBPX110 mm Hg) were excluded, as well as those with SeSBPo130 mm Hg. Patients were also excluded if they had malignant, accelerated or secondary hypertension, or were in need of immediate blood pressure-lowering therapy. Patients with hypertensive encephalopathy, stroke or transient ischaemic attack within the past 12 months, or unstable angina, myocardial infarction or coronary grafting or revascularization within the past 6 months, were excluded. Among the other exclusion criteria were significant chronic renal impairment or renovascular disease, hepatic disease, systemic lupus erythematosus, malignancy, gastrointestinal disease or gastrointestinal surgery that might interfere with drug absorption. Patients could not participate if they had a history of drug or alcohol abuse, or had any medical or psychiatric condition that might confound assessment of study medication or jeopardize the patient's safety. Women of childbearing potential were eligible to participate, provided they had a negative pregnancy test within 72 h of the start of study medication and used an adequate method of contraception, both during the study and for up to 1 week after study completion. Pregnant or lactating women were not eligible to participate.
The study was conducted at 135 centres in the USA, Canada, France and Germany. Ethics Committee and/or Institutional Review Board approval was granted at all participating centres, and all patients gave written informed consent prior to enrolment. The study was conducted in accordance with the ethical principles of the current Declaration of Helsinki and consistent with the International Conference on Harmonization Good Clinical Practice.
Study design
This was a randomized, double-blind, active-controlled, parallel-group study of 12 weeks' duration. Eligible patients entered a 21-day single-blind, placebo wash-out period before randomization in a 3:1:1 ratio to 12 weeks of active treatment. Patients randomized to combination therapy received fixeddose irbesartan 150 mg/HCTZ 12.5 mg for 2 weeks followed by forced titration to irbesartan 300 mg/ HCTZ 25 mg for the remaining 10 weeks, while those on irbesartan monotherapy received 2 weeks of irbesartan 150 mg followed by 10 weeks of irbesartan 300 mg. Patients in the HCTZ treatment group received HCTZ 12.5 mg for 2 weeks, increased to HCTZ 25 mg for the remaining 10 weeks. Study drugs together with matching placebo were taken once daily between 0600 and 1100 hours except on the morning of a study visit so that blood pressure could be measured at trough (that is, 2473 h following the last dose of study medication). Concomitant administration of vasoactive drugs, any drug or herbal preparation likely to affect blood pressure, as well as those likely to interact with study medication, was prohibited throughout the study.
Efficacy assessments
Blood pressure and heart rate were measured using a sponsor-provided automatic blood pressure monitor. In the USA and Canada, an OMRON HEM-712CN (Omron Healthcare Inc., Bannockburn, IL, USA) was provided, whereas in Europe, an OMRON MX3 (Omron Healthcare Europe BV, Hoofddorp, The Netherlands) was employed. Both models were tested and recommended against two protocols, those from the Association for the Advancement of Medical Instruments and the International Protocol of the European Society of Hypertension, for accuracy. 22 Patients rested for a minimum of 10 min in a seated position before any measurements were taken. An average of 3-5 replicate SeBP measurements were obtained at least 1 min apart followed by an average of three replicate measures of standing blood pressure. Measurements were taken from both arms and the arm with the higher reading used in those cases where blood pressure readings differed between arms. This same arm was used to obtain trough blood pressure readings at all subsequent study visits, which included day 14 of the singleblind, placebo wash-out period, before randomization to double-blind treatment on day 21 and at weeks 2, 4, 8 and 12 of double-blind treatment.
An IMMULITE 2000 high-sensitivity CRP analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA) was used to measure high-sensitivity C-reactive protein (hs-CRP) levels in blood samples obtained at baseline and at weeks 8 and 12.
The primary efficacy end point was change in SeSBP after week 8. Secondary efficacy end points included change from baseline in SeDBP at weeks 8 and 12, change from baseline in SeSBP at week 12 and the proportion of subjects who met JNC-7 criteria of blood pressure control, that is with simultaneous SeSBPo140 mm Hg and SeDBP o90 mm Hg at weeks 8 and 12.
Safety assessments
On enrolment to the study, all patients gave a detailed medical history and underwent a complete physical examination, including a 12-lead electrocardiogram. Blood and urine samples for laboratory analyses were collected at baseline, before randomization to doubleblind treatment on day 21 and at weeks 2, 4, 8 and 12 of the double-blind active treatment period.
Safety was assessed in all randomized patients who took at least 1 dose of study medication. The frequency and severity of adverse events (AEs) as well as their relationship to study medication were summarized. Adverse events related to aggressive blood pressure-lowering therapy, including hypotension, dizziness, syncope and headaches, as well as the frequency of hypokalaemia and hyperkalaemia at week 12, were prespecified as secondary outcome measures in this study. The incidences of clinical laboratory test abnormalities during doubleblind treatment were also summarized.
Statistical analysis
This study was designed to test the hypothesis that after 8 weeks of double-blind treatment in patients with moderate hypertension, the reduction in baseline SeSBP would be greater following treatment with combination therapy than with either irbesartan or HCTZ monotherapy alone.
A sample size of 298 patients in the combination treatment arm and 99 patients in each of the two monotherapy arms was chosen to provide at least 90% power at a one-sided significance level of 0.025 to detect a 6.0 mm Hg difference between combination therapy and monotherapy in change from baseline in SeSBP at week 8. This sample size would also give 90% power to detect an overall difference of 3.2 mm Hg between combination therapy and monotherapy in change from baseline in SeDBP at week 8. The sample size calculation assumed a standard deviation of 14 and 7.5 mm Hg for change in SeSBP and SeDBP, respectively, and also allowed for a 5% dropout rate.
All efficacy analyses were made on an intent-totreat basis, using the data set of all randomized subjects. Changes in SeSBP and SeDBP from baseline to week 8 were compared between treatment groups using one-way analysis of covariance, with baseline blood pressure (seated systolic and seated diastolic) as the covariate. Combination therapy was considered statistically significantly superior if the larger of the two one-sided P-values obtained by testing combination therapy separately against the two monotherapy groups was o0.025; the 'min' test of Laska and Meisner 23 is inherently one-sided. Analysis of covariance was also used for secondary efficacy end points, in which treatment was the main effect and baseline value the covariate. The covariate-adjusted mean difference between the combination treatment group and each monotherapy regimen was tested at the two-sided 5% significance level.
Results

Patient disposition
In total, 769 patients were enrolled, of whom 538 were randomized to study medication and began double-blind treatment. Of the 231 patients who were enrolled but not randomized, the large majority (187) were excluded because they no longer met study criteria. The number of patients receiving irbesartan/HCTZ combination therapy, irbesartan monotherapy and HCTZ monotherapy was 328, 106 and 104, respectively. A total of 472 patients (87.7% of randomized patients) completed double-blind treatment, while similar numbers discontinued prematurely in all three groups-41 patients (12.5%), 12 patients (11.3%) and 13 patients (12.5%) in the irbesartan/HCTZ, irbesartan and HCTZ groups, respectively. The single most common reason for premature withdrawal was AEs. One patient in each group withdrew due to lack of efficacy.
Baseline characteristics
The treatment groups were similar at baseline with respect to demographic and clinical characteristics (Table 1) . Most patients were middle-aged: the mean age was approximately 55 years and 71.5% were between the ages of 40 and 64 years. Overall, 81 (15.1%) were aged 65-74 years and 29 (5.4%) were aged 75 or older. Some 292 subjects (55%) were male; 452 (84.0%) were white and 74 (13.8%) were black/African-American. At baseline, the mean sitting blood pressure was 161.7/97.5 mm Hg. Overall, 228 patients (42.4%) had hyperlipidemia, while 74 (13.8%) had diabetes mellitus. Patients with a prior history of angina pectoris, myocardial infarction or stroke/transient ischaemic attack were fewer than 2% in all three groups. In total, 52.4, 49.1 and 45.2% of subjects in the irbesartan/HCTZ, irbesartan and HCTZ groups, respectively, had previously received antihypertensive therapy.
Efficacy
Irbesartan/HCTZ combination therapy reduced blood pressure to a greater degree than either irbesartan or HCTZ monotherapy. With regard to the primary efficacy variable, the mean reductions in SeSBP from baseline to week 8 were 27.1 mm Hg in the irbesartan/HCTZ group, compared with 22.1 mm Hg in the irbesartan group (P ¼ 0.0016) and 15.7 mm Hg in the HCTZ group (Po0.0001; Figure 1) . Similarly, mean reductions in SeDBP from baseline to week 8 were 14.6 mm Hg in the irbesartan/HCTZ group, compared with 11.6 mm Hg in the irbesartan group (P ¼ 0.0013) and 7.3 mm Hg in the HCTZ group (Po0.0001).
Similar blood pressure-lowering responses were observed when the results were stratified according to whether patients were previously untreated or had been transferred from insufficiently effective antihypertensive medications. At week 8, the mean reductions in SeSBP with irbesartan/HCTZ were 28.2 and 26.0 mm Hg in the previously treated and previously untreated groups, respectively. Mean reductions in SeDBP were 14.2 and 15.0 mm Hg in the previously treated and previously untreated groups, respectively. Comparable data were observed in the irbesartan and HCTZ monotherapy groups. The magnitude of response to treatment in diabetic and non-diabetic patients was also comparable to that in the study population as a whole, as was that observed in the obese and dyslipidaemic subgroups (data not shown).
With regard to the time course of blood pressure reduction, significantly greater reductions in both SeSBP and SeDBP in the combination therapy group were observed at all time points, with increasing reductions in blood pressure throughout the course of the study (Figure 2 ). Both the rate of decline and the total degree of decline achieved were greatest with irbesartan/HCTZ combination therapy and least with HCTZ monotherapy.
As shown in Figure 3 , similar results were observed with regard to the proportion of patients reaching a treatment target of SeSBP o140 mm Hg and SeDBP o90 mm Hg. In total, 53.4% of patients in the irbesartan/HCTZ arm were controlled by week 8, compared with 40.6% of patients in the irbesartan monotherapy arm (P ¼ 0.0254) and 20.2% in the HCTZ arm (Po0.0001). By week 12, 55.8% of patients in the irbesartan/HCTZ group had controlled blood pressure as defined by JNC-7 criteria. 
Safety and tolerability
Treatment was well tolerated in all three arms of the study. The overall frequency of AEs during doubleblind treatment period was similar in the three treatment groups (Table 2) . Treatment-related AEs were more common in the combination arm (14.3%) than in the irbesartan monotherapy (11.3%) and HTCZ group (7.7%). There were six serious AEs in the irbesartan/HCTZ combination arm, only one of which was considered related to study medication: this was a reported case of hypokalaemia that was mild in severity. There were no serious AEs in the irbesartan monotherapy group and there were three AEs in the HCTZ group, none of which were considered related to study therapy. The percentages of patients discontinuing treatment due to an AE were 6.7, 3.8 and 4.8% in the irbesartan/HCTZ, irbesartan and HCTZ groups, respectively. Withdrawals due to dizziness (four subjects) and hypotension (three subjects) were both observed in the irbesartan/HCTZ group, but these events were infrequent and occurred primarily following forced titration in patients in whom blood pressure was already controlled. Overall, the incidence of prespecified AEs was somewhat greater in the combination therapy group (10.7% of patients, compared with 6.6 and 6.7% in the irbesartan and HCTZ monotherapy groups, respectively). Headache was the most common prespecified AE in all three groups. There was one reported episode of syncope-this occurred in the HCTZ monotherapy group following upwards titration of the dose. Increases or decreases in serum potassium were each reported in approximately 1% of subjects in the combination therapy group; at week 12, there was a mean decrease in serum potassium of À0.14 mEq l À1 in this group compared with baseline, and of À0.3 mEq l À1 in the HCTZ monotherapy group. There was no change in the irbesartan monotherapy group.
There were 10 subjects (3.1%) in the irbesartan/ HCTZ combination therapy group with a value consistent with the criteria for a marked elevation in creatinine, compared to 3 (2.9%) and 5 (4.9%) in the irbesartan and HCTZ monotherapy groups, respectively. It should be noted that the definition of marked laboratory abnormality included relatively small changes that could still be in the normal range, since any value 41.5 times the pretreatment value was considered a marked abnormality. The highest serum creatinine value reported for a subject in whom a renal and urinary AE was reported was 1.3 mg per 100 ml, observed in a subject whose baseline serum creatinine was 1.2 mg per 100 ml; the highest creatinine value seen during the study in any subject was 1.7 mg per 100 ml.
None of the other laboratory tests revealed any findings of concern. In tests of creatine kinase, serum glucose, uric acid and albumin, there were modest numbers (three instances, 0.9%) of abnormalities in Figure 1 Adjusted mean change in trough seated systolic blood pressure (SeSBP) and trough seated diastolic blood pressure (SeDBP) from baseline to week 8. Error bars denote standard error. P-values refer to comparisons with combination therapy.
the irbesartan/HCTZ combination therapy group. The irbesartan monotherapy group had four instances (4.0%) and the HCTZ monotherapy group had none. There were no instances of an abnormal change in total cholesterol level in any study subject.
Discussion
Hypertensive patients should be treated with the objective of attaining blood pressure goals fully and rapidly, since significant delays or failure to achieve goals are associated with an increased risk of cardiovascular events. 24 Since patients with moderate or severe hypertension are likely to require two or more agents to reach goal, current JNC-7 and European Society of Hypertension guidelines both recommend the use of initial combination therapy to manage their blood pressure. 15, 16 This large study involving 558 patients investigated the efficacy and safety of irbesartan/HCTZ 300/ 25 mg in subjects with moderate hypertension, with approximately equal numbers of previously untreated patients and those in whom prior therapy had been inadequate. The clinical profile of the study participants was broad and representative of the general hypertensive population, and included patients who were diabetic, obese and/or dyslipidaemic. Irbesartan/HCTZ combination therapy proved highly effective in lowering blood pressure: the mean reduction in blood pressure after 8 weeks was 27.1/ 14.6 mm Hg for irbesartan 300 mg/HCTZ 25 mg, a significantly greater reduction than with irbesartan or HCTZ monotherapy, thereby confirming the primary hypothesis of the study that the combination would deliver superior control in this high-risk, difficult-totreat patient population. The response to treatment was rapid and sustained, with increasing reductions in blood pressure throughout the course of the trial. Moreover, patients who had previously responded inadequately to treatment were found to have the same reductions in blood pressure as previously untreated patients, emphasizing the blood pressurelowering effectiveness of the irbesartan/HCTZ combination. The response in diabetic and non-diabetic subgroups was also comparable to that observed in the study population as a whole, although in this study the diabetic subgroup was quite small, at around 13.8% of the total.
The proportion of patients achieving blood pressure goals was also greater in the combination therapy arm, with over 55% of patients reaching a target of below 140/90 mm Hg, compared with 40.6 and 20.2% in the irbesartan and HCTZ monotherapy groups, respectively. This rate of goal attainment indicates that this two-drug combination is effective in this patient group, many of whom had been unsuccessfully treated by prior antihypertensives.
Of note, irbesartan monotherapy was also more effective than HCTZ monotherapy during the course of the trial, with mean reductions in SeDBP from baseline to week 8 of 11.6 and 7.3 mm Hg in the irbesartan and HCTZ monotherapy groups, respectively (difference 4.4 mm Hg, 95% CI 6.6-2.1). The observation that HCTZ-treated patients responded so poorly is not surprising, as HCTZ 12.5 mg is not Irbesartan monotherapy significantly reduced hs-CRP at week 12, although the variability was high and no significant changes were observed at earlier time points. No significant changes were observed in the HCTZ monotherapy and irbesartan/HCTZ combination groups. Similar findings were reported in a recent study of valsartan/HCTZ combination therapy, in which there was a slight increase in hs-CRP levels with the HCTZ combination, compared with a significant reduction when valsartan was given in monotherapy. 25 In the valsartan study, this difference was reported to be unrelated to the greater reduction of blood pressure in the combination therapy group. The effects of thiazide combination on the anti-inflammatory effects of ARBs require further investigation. A larger sample size or longer observation period may be required to characterize these effects better.
Safety and tolerability is a critical consideration in aggressive hypertensive therapy, which can be associated with hypotension, syncope, headache and hypokalaemia. In this study, the three treatment arms were well tolerated. There was a numerically greater incidence of some treatment-related effects, including headache, hypotension and hypokalaemia with irbesartan/HCTZ combination therapy, but the treatment was well tolerated and there was no excess of withdrawals. There were no episodes of syncope in the study, with the exception of a single case in the HCTZ monotherapy group following titration. These findings vindicate the approach of the JNC-7 and European Society of Hypertension in recommending aggressive, two-drug therapy as initial treatment for patients with moderate hypertension, and indicate that this strategy can be pursued without compromising patient safety. These results are also consistent with two other irbesartan/HCTZ studies, which also found that combination therapy-even in patients with severe hypertensionwas well tolerated with no major AEs reported. 21, 26 Fixed-dose combinations are likely to become an increasingly important option in the management of hypertension as the drive to improve the simplicity and convenience of treatment continues. The results of this study demonstrate that an irbesartan/HCTZ combination was effective in a population of patients with moderate hypertension, a significant proportion of whom had not received prior antihypertensive treatment. It should be noted, however, that differences in blood pressure-lowering efficacy demonstrated between ARBs when these agents are used in monotherapy have been found to be replicated in the setting of HCTZ combination therapy. For instance, irbesartan 150 mg has been found to reduce blood pressure to a significantly greater degree than valsartan 80 mg at equivalent doses both in monotherapy 27 and, more recently, when both agents were given in combination with HCTZ. 28 Therefore, caution should be exercised when extending these results to other agents in the ARB class, and ideally data should be obtained for individual ARBs.
In conclusion, these results indicate that irbesartan/HCTZ is effective, has a favourable safety profile and is well tolerated in patients with moderate hypertension, whether used as initial therapy or in patients not controlled on monotherapy. Treatment achieved substantial reductions in both systolic and diastolic blood pressure, and enables over half of patients to reach a target blood pressure of below 140/90 mm Hg without the need for additional medication. These results support the use of the irbesartan/HCTZ fixed-dose combination in the management of moderate hypertension.
